Related Experiment Video
Updated: Aug 16, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Effects of navelbine and docetaxel on gene expression in lung cancer cell strains
Li Cai1, Hai-ying Dong, Guang-jie Sui
1Internal Medicine of Oncology, the Third Affiliated Hospital of Harbin Medical University, Harbin 150040, China. caiwenxin76@yahoo.com.cn
Aim:
To search genes sensitivity to the anti-cancer drugs navelbine (NVB) and docetaxel (DOC) in small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) cell strains.
Methods:
The sensitivity of 4 strains of SCLC and 6 strains of NSCLC to NVB and DOC was evaluated using the MTT assay. The expression of 1291 sensitive-related genes to the anti-cancer drugs in 10 lung cancer cell strains was measured using cDNA macroarrays and the relationship was analyzed.
Results:
In total, there were 56 (r > or = 0.4) genes sensitive to NVB and DOC. For NVB: 36 genes were sensitive to NVB, 20 co-expressed genes between the SCLC+NSCLC set and the NSCLC set; 27 expressed genes and 7 specially expressed genes in the SCLC+NSCLC set; and 29 expressed genes and 9 specially expressed genes in the NSCLC set. For DOC, 50 genes were sensitive to DOC, 12 co-expressed genes between the SCLC+NSCLC set and the NSCLC set; 24 expressed genes and 12 specially expressed genes in the SCLC+NSCLC set; and 38 expressed genes and 26 specially expressed genes in the NSCLC set. The genes sensitive to NVB and DOC in lung-cancer cell stains were mainly divided into the following 4 categories: signal transduction molecules, cell factors, transcription factors and metabolism-related enzymes and inhibitors.
Conclusions:
There were obvious differences in genes related to NVB and DOC between SCLC and NSCLC cell strains, but the same as categories of function.
Insights
This study identified 56 genes sensitive to navelbine (NVB) and docetaxel (DOC) in lung cancer cells. Gene sensitivity to these anti-cancer drugs differs between small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) strains.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer, including small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), remains a leading cause of cancer-related mortality.
- Navelbine (NVB) and docetaxel (DOC) are chemotherapeutic agents used in lung cancer treatment.
- Understanding the genetic basis of drug sensitivity is crucial for optimizing treatment strategies.
Purpose of the Study:
- To identify genes associated with sensitivity to navelbine (NVB) and docetaxel (DOC) in both SCLC and NSCLC cell lines.
- To analyze the differential gene expression patterns in response to NVB and DOC between SCLC and NSCLC.
- To categorize the identified sensitive genes based on their functional roles.
Main Methods:
- Utilized the MTT assay to evaluate the sensitivity of 4 SCLC and 6 NSCLC cell strains to NVB and DOC.
- Employed cDNA macroarrays to measure the expression of 1291 drug-sensitive genes across 10 lung cancer cell strains.
- Performed correlation analysis to identify relationships between gene expression and drug sensitivity.
Main Results:
- Identified a total of 56 genes significantly correlated with NVB and DOC sensitivity (r >= 0.4).
- For NVB, 36 sensitive genes were identified, with specific subsets uniquely or co-expressed in SCLC and NSCLC.
- For DOC, 50 sensitive genes were identified, also showing distinct expression patterns between SCLC and NSCLC.
- Sensitive genes were broadly categorized into signal transduction molecules, cell factors, transcription factors, and metabolism-related enzymes/inhibitors.
Conclusions:
- Significant differences exist in gene sensitivity to NVB and DOC between SCLC and NSCLC cell strains.
- Despite differences in specific genes, the functional categories of NVB- and DOC-sensitive genes were similar across both lung cancer subtypes.
- These findings provide insights into the molecular mechanisms underlying differential drug responses in lung cancer.
